Integration of interferon-α/β signalling to p53 responses in tumour suppression and antiviral defence
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
Swift elimination of undesirable cells is an important feature in tumour suppression and immunity. The tumour suppressor p53 and interferon-alpha and -beta (IFN-alpha/beta) are essential for the induction of apoptosis in cancerous cells and in antiviral immune responses, respectively, but little is known about their interrelationship. Here we show that transcription of the p53 gene is induced by IFN-alpha/beta, accompanied by an increase in p53 protein level. IFN-alpha/beta signalling itself does not activate p53; rather, it contributes to boosting p53 responses to stress signals. We show examples in which p53 gene induction by IFN-alpha/beta contributes to tumour suppression. Furthermore, we show that p53 is activated in virally infected cells to evoke an apoptotic response and that p53 is critical for antiviral defence of the host. Our study reveals a hitherto unrecognized link between p53 and IFN-alpha/beta in tumour suppression and antiviral immunity, which may have therapeutic implications.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In response to senesce-inducing stimuli, senescent cells produce, in a cGAS-dependent manner, type I interferons that have pro-senescence and anti-proliferative activities.”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
In the citing paper
“Indeed, β-interferons increase ROS production, leading to DNA damage and p53 activation [273,274].”
From Mechanisms and Regulation of Cellular Senescence (2021) · cites this paper as [273]
Citations
Cites
Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
Darnell, J. E., Kerr, L. M., & Stark, G. R. (1994) · Science · doi:10.1126/science.8197455 · Cited by 6,080 · cited 1×
“2a ); ISRE is activated by the IFN-activated transcription factor ISGF3, a heterotrimeric complex consisting of a signal transducer and activator of transcription factor 1 (Stat1), Stat2 and interferon regulatory factor 9 (IRF-9”
BackgroundMice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · cited 1×
“Previous studies have shown that p53 -deficient mice show no sign of abnormality in T and B cells, and that they can mount adaptive immune responses normall”
ResultMdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodPapillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024 · cited 1×
“Persistent infection with oncogenic HPV types represents a major risk factor for the development of cervical cancer, in which E6 is known to have a critical role (together with another oncoprotein, E7 (ref”
BackgroundDNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 1×
“We infer that, similar to DNA damage, ATM activation is caused by changes in the chromatin structure in virus-infected cell”
BackgroundRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“We performed a pulse–chase experiment to examine whether the observed p53 protein induction is secondary to suppression of the p53 degradation pathway by IFN-β, typically the MDM2-mediated pathwa”
MethodLive or let die: the cell's response to p53
Vousden, K. H., & Lu, X. (2002) · Nature Reviews Cancer · doi:10.1038/nrc864 · Cited by 3,192
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925 · cited 1×
“We also examined the effect of IFN-β on the DNA damage-induced apoptotic response of MEFs expressing the adenovirus E1A oncoprotein, as it is well known that this response is p53-dependent and critical for tumour suppressio”
BackgroundNoxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Self-citation
Research works printed but not linked: 1
- Vilcek, J. & Sen, G. S. in Fields Virology 3rd edn (eds Fields, D. M., Knipe, P. M. & Howley, P. M.) 375–399 (Lippincott-Raven, Philadelphia, 1996)
Cited by
Items 201–300 of 867
Han, J., Yl, K., Lee, K.-W., Her, N.-G., Ha, T.-K., Yoon, S., Jeong, S.-I., Lee, J.-H., Kang, M. J., Lee, M.-G., et al. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.33 · Cited by 74
Macrophages, Inflammation, and Tumor Suppressors: ARF, a New Player in the Game
Través, P. G., Luque, A., & Hortelano, S. (2012) · Mediators of Inflammation · doi:10.1155/2012/568783 · Cited by 68
“Activation of p53 by IFN has been reported [80, 81] and p53-deficient mice are more permissive to viral infection [82].”
BackgroundInfluentialBalasubramanian, N., Bai, P., Buchek, G., Korza, G., & Weller, S. K. (2010) · Journal of Virology · doi:10.1128/jvi.01506-10 · Cited by 78
DRAM Triggers Lysosomal Membrane Permeabilization and Cell Death in CD4+ T Cells Infected with HIV
Laforge, M., Limou, S., Harper, F., Casartelli, N., Rodrigues, V., Silvestre, R., Haloui, H., Zagury, J.-F., Senik, A., & Estaquier, J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003328 · Cited by 70
Interleukin-12: Clinical usage and molecular markers of cancer susceptibility
Yuzhalin, A. E., & Kutikhin, A. G. (2012) · Growth Factors · doi:10.3109/08977194.2012.678843 · Cited by 78
Sun, Y., & Leaman, D. W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412630200 · Cited by 86
Shang, D., Liu, Y., Matsui, Y., Ito, N., Nishiyama, H., Kamoto, T., & Ogawa, O. (2008) · Urology · doi:10.1016/j.urology.2007.11.029 · Cited by 70
Development of novel treatments for hepatitis C
Webster, D. P., Klenerman, P., Collier, J. D., & Jeffery, K. J. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70020-9 · Cited by 81
Ruby, T., Whittaker, C., Withers, D. R., Chelbi‐Alix, M. K., Morin, V., Oudin, A., Young, J. R., & Zoorob, R. (2006) · Journal of Virology · doi:10.1128/jvi.00929-06 · Cited by 87
p53: a heavily dictated dictator of life and death
Lü, X. (2004) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2004.12.008 · Cited by 80
Goubau, D., Romieu, R., Solis, M., Hernandez, E., Mésplède, T., Lin, R., Leaman, D. W., & Hiscott, J. B. (2009) · European Journal of Immunology · doi:10.1002/eji.200838832 · Cited by 75
Zhang, H. M., Ji, Y., Cheung, P., Chau, D., Wong, B. W., McManus, B. M., & Yang, D. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.14.6247-6258.2005 · Cited by 74
Yamashita, T., Arai, K., Sunagozaka, H., Ueda, T., Terashima, T., Yamashita, T., Mizukoshi, E., Sakai, A., Nakamoto, Y., Honda, M., et al. (2011) · Oncology · doi:10.1159/000334439 · Cited by 67
Mizutani, T., Neugebauer, N., Putz, E. M., Moritz, N., Simma, O., Zebedin-Brandl, E., Gotthardt, D., Warsch, W., Eckelhart, E., Kantner, H.-P., et al. (2012) · OncoImmunology · doi:10.4161/onci.21284 · Cited by 68
Self-citationMiR-122 modulates type I interferon expression through blocking suppressor of cytokine signaling 1
Li, A., Song, W., Qian, J., Li, Y., He, J., Zhang, Q., Li, W., Zhai, A., Kao, W., Hu, Y., et al. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.01.008 · Cited by 67
Growing tumors induce a local STING dependent Type I IFN response in dendritic cells
Andzinski, L., Spanier, J., Kasnitz, N., Kröger, A., Jin, L., Brinkmann, M. M., Kalinke, U., Weiss, S., Jablonska, J., & Lienenklaus, S. (2016) · International Journal of Cancer · doi:10.1002/ijc.30159 · Cited by 66
Mallia, P., Contoli, M., Caramori, G., Pandit, A., Johnston, S. L., & Papi, A. A. (2006) · Current Pharmaceutical Design · doi:10.2174/138161207779313777 · Cited by 76
Khan, M. K., & Almasan, A. (2011) · OncoTargets and Therapy · doi:10.2147/ott.s20257 · Cited by 69
A Critical Role for Interferon Regulatory Factor 9 in Cerebral Ischemic Stroke
Chen, H., Guo, S., Li, Z.-Z., Lu, Y., Jiang, D.-S., Zhang, R., Lei, H. C., Gao, L., Zhang, X., Zhang, Y., et al. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1545-14.2014 · Cited by 68
“Furthermore, p53 transcription cannot be induced by IFN- / in the absence of IRF9 (Takaoka et al., 2003).”
BackgroundRossi, E. A., Goldenberg, D. M., Cardillo, T. M., Stein, R., & Chang, C. (2009) · Blood · doi:10.1182/blood-2009-06-228890 · Cited by 68
Roles of p53 in Herpes Simplex Virus 1 Replication
Maruzuru, Y., Fujii, H., Oyama, M., Kozuka‐Hata, H., Kato, A., & Kawaguchi, Y. (2013) · Journal of Virology · doi:10.1128/jvi.01581-13 · Cited by 67
“Studies of the role of p53 in HSV-1 replication in vivo would be of particular interest, since p53, whose expression can be regulated by interferons, has been reported to contribute to immune responses for neutralization of pathogens (61).”
BackgroundMutual reinforcement of inflammation and carcinogenesis by the Helicobacter pylori CagA oncoprotein
Suzuki, N., Murata‐Kamiya, N., Yanagiya, K., Suda, W., Hattori, M., Kanda, H., Bingo, A., Fujii, Y., Maeda, S., Koike, K., et al. (2015) · Scientific Reports · doi:10.1038/srep10024 · Cited by 72
Potential contribution of tumor suppressor p53 in the host defense against hepatitis C virus†
Dharel, N., Kato, N., Muroyama, R., Taniguchi, H., Otsuka, M., Wang, Y., Jazag, A., Shao, R., Chang, J., Adler, M. K., et al. (2008) · Hepatology · doi:10.1002/hep.22176 · Cited by 65
Reu, F. J., Leaman, D. W., Maitra, R. R., Bae, S. I., Cherkassky, L., Fox, M. W., Rempinski, D., Beaulieu, N., MacLeod, A. R., & Borden, E. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2303 · Cited by 70
Katamura, Y., Aikata, H., Takaki, S., Azakami, T., Kawaoka, T., Waki, K., Hiramatsu, A., Kawakami, Y., Takahashi, S., Kenjo, M., et al. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0033-y · Cited by 64
Zhang, Y., Liu, X., She, Z., Jiang, D.-S., Wan, N., Xia, H., Zhu, X., Xiang, W., Zhang, X., & Li, H. (2014) · Basic Research in Cardiology · doi:10.1007/s00395-014-0434-9 · Cited by 65
Ru, J., Sun, H., Fan, H., Wang, C., Li, Y., Liu, M., & Tang, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114021 · Cited by 64
ISG15 inhibits cancer cell growth and promotes apoptosis
Zhou, M., Chen, F.-Z., Chen, H., Wan, X.-X., Zhou, X., Fang, Q., & Zhang, D. (2016) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2016.2845 · Cited by 64
Herzer, K., Weyer, S., Krammer, P. H., Galle, P. R., & Hofmann, T. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0880 · Cited by 72
“Interestingly, a recent report identified p53 as a key regulator of IFN-a/h-mediated antiviral response (12).”
BackgroundRegulation of MCP-1 chemokine transcription by p53
Hacke, K., Rincon-Orozco, B., Buchwalter, G., Siehler, S. Y., Wasylyk, B., Wiesmüller, L., & Rösl, F. (2010) · Molecular Cancer · doi:10.1186/1476-4598-9-82 · Cited by 63
Chen, H., Tanaka, N., Mitani, Y., Oda, E., Nozawa, H., Chen, J., Yanai, H., Negishi, H., Choi, M. K., Iwasaki, T., et al. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.01051.x · Cited by 63
Self-citationp53 integrates host defense and cell fate during bacterial pneumonia
Madenspacher, J. H., Azzam, K. M., Gowdy, K. M., Malcolm, K. C., Nick, J. A., Dixon, D., Aloor, J. J., Draper, D. W., Guardiola, J. J., Shatz, M., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20121674 · Cited by 63
“These investigations have been limited to viral inoculation (Takaoka et al., 2003; Turpin et al., 2005; Muñoz-Fontela et al., 2008), a setting in which cell-intrinsic hallmark functions of p53 established in the tumor suppressor literature (e.g., cell cycle arrest and apoptosis) had also already…”
BackgroundInterferon α in cancer immunoediting: From elimination to escape
Vidal, P. D. (2020) · Scandinavian Journal of Immunology · doi:10.1111/sji.12863 · Cited by 69
A Dual Role of Type I Interferons in Antitumor Immunity
Zhou, L., Zhang, Y., Wang, Y., Zhang, M., Sun, W., Dai, T., Wang, A., Wu, X., Zhang, S., Wang, S., et al. (2020) · Advanced Biosystems · doi:10.1002/adbi.201900237 · Cited by 64
Smith, J. N. P., Kanwar, V. S., & MacNamara, K. C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00330 · Cited by 73
Ninjurin 1 has two opposing functions in tumorigenesis in a p53-dependent manner
Yang, H. J., Zhang, J., Yan, W., Cho, S.-J., Lucchesi, C. A., Chen, M., Huang, E. C., Scoumanne, A., Zhang, W., & Chen, X. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711814114 · Cited by 65
The Evolving Role of Taurolidine in Cancer Therapy
Neary, P., Hallihan, P., Wang, J. H., Pfirrmann, R. W., Bouchier‐Hayes, D. J., & Redmond, H. P. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0867-9 · Cited by 69
“The p53 protein is a tumor-suppressor protein and an increase results in enhancement of cancer cell apoptosis.(59) Therefore, it is apparent that taurolidine’s tumoricidal effect is multifaceted.”
BackgroundLife and Death Decision-Making by p53 and Implications for Cancer Immunotherapy
Liu, Y. U., Leslie, P. L., & Zhang, Y. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.10.005 · Cited by 69
“positive feedback loop [52], subsequently triggering p53-dependent apoptosis to eliminate virally infected cells and prevent virus spread [53, 54].”
BackgroundOoi, E. L., Verján, N., Haraguchi, I., Oshima, T., Kondo, H., Hırono, I., Aoki, T., Kiyono, H., & Yuki, Y. (2008) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2008.03.010 · Cited by 65
Adenoviral Vector-Based Strategies for Cancer Therapy
Sharma, A., Tandon, M., Bangari, D. S., & Mittal, S. K. (2009) · Current Drug Therapy · doi:10.2174/157488509788185123 · Cited by 68
Hubackova, S., Novakova, Z., Krejcikova, K., Kosar, M., Dobrovolna, J., Duskova, P., Hanzlikova, H., Vancurova, M., Barath, P., Bartek, J., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.15.12521 · Cited by 56
Takeuchi, T., Iwahara, S., Saeki, Y., Sasajima, H., & Yokosawa, H. (2005) · The Journal of Biochemistry · doi:10.1093/jb/mvi172 · Cited by 58
A molecular arms race between host innate antiviral response and emerging human coronaviruses
Wong, L.-Y. R., Lui, P., & Jin, D. (2016) · Virologica Sinica · doi:10.1007/s12250-015-3683-3 · Cited by 60
“For example, IFN-inducible gene p53 evokes apoptosis in virus-infected cells (Takaoka et al., 2003).”
BackgroundImpact of host immunity on HTLV-1 pathogenesis: potential of Tax-targeted immunotherapy against ATL
Kannagi, M., Hasegawa, A., Nagano, Y., Kimpara, S., & Suehiro, Y. (2019) · Retrovirology · doi:10.1186/s12977-019-0484-z · Cited by 64
The Importance of Physiologically Relevant Cell Lines for Studying Virus–Host Interactions
Hare, D. N., Collins, S. E., Cuddington, B., & Mossman, K. L. (2016) · Viruses · doi:10.3390/v8110297 · Cited by 63
Use of attenuated paramyxoviruses for cancer therapy
Lech, P. J., & Russell, S. J. (2010) · Expert Review of Vaccines · doi:10.1586/erv.10.124 · Cited by 62
Imbeault, M., Ouellet, M., & Tremblay, M. J. (2009) · Retrovirology · doi:10.1186/1742-4690-6-5 · Cited by 65
Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response
Marques, J. T., Rebouillat, D., Ramana, C. V., Murakami, J., Hill, J. E., Gudkov, A., Silverman, R. H., Stark, G. R., & Williams, B. R. G. (2005) · Journal of Virology · doi:10.1128/jvi.79.17.11105-11114.2005 · Cited by 59
“p53 is an important mediator of stress responses, and previous observations have implicated p53 in antiviral defense against VSV ( 38 ).”
BackgroundMethodResultInfluentialZhu, F. X., Sathish, N., & Yuan, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010573 · Cited by 57
Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia
Tomic, J., Lichty, B. D., & Spaner, D. (2011) · Blood · doi:10.1182/blood-2010-05-285999 · Cited by 60
Anuja, K., Roy, S., Ghosh, C., Gupta, P., Bhattacharjee, S., & Banerjee, B. (2016) · Inflammation Research · doi:10.1007/s00011-016-0985-3 · Cited by 64
Lallemand, C., Blanchard, B., Palmieri, M., Lebon, P., May, E., & Tovey, M. G. (2006) · Oncogene · doi:10.1038/sj.onc.1209795 · Cited by 58
“Thus, the finding that vesicular stomatis virus (VSV) infection can activate the p53 protein (Takaoka et al., 2003) suggests that p53 may play a role in virus-induced apoptosis, whereas on the other hand, destabilization of the p53 reported during ssRNA virus infection suggests that p53 degradation…”
BackgroundAntiviral action of the tumor suppressor ARF
García, M. Á., Collado, M., Muñoz‐Fontela, C., Matheu, A., Marcos-Villar, L., Arroyo, J., Estéban, M., Serrano, M., & Rivas, C. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601302 · Cited by 62
“The activation of some of these tumor suppressors by IFN treatment (Mecchia et al, 2000; Takaoka et al, 2003), a factor with potent antioncogenic and antiviral activities, strengthens this speculation.”
BackgroundInfluentialTargeting IFN-α to B Cell Lymphoma by a Tumor-Specific Antibody Elicits Potent Antitumor Activities
Huang, T.-H., Chintalacharuvu, K. R., & Morrison, S. L. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.10.6881 · Cited by 51
Schuliga, M. J., Kanwal, A., Read, J. M., Blokland, K. E. C., Burgess, J. K., Prêle, C. M., Mutsaers, S. E., Grainge, C., Thomson, C., James, A., et al. (2021) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00574.2020 · Cited by 58
Sakaguchi, Y., Kudo, M., Fukunaga, T., Minami, Y., Chung, H., & Kawasaki, T. (2005) · Intervirology · doi:10.1159/000082097 · Cited by 54
Sathish, N., & Yuan, Y. (2011) · Journal of Virology · doi:10.1128/jvi.00687-11 · Cited by 57
Kumari, P., Saha, I., Narayanan, A., Narayanan, S., Takaoka, A., Kumar, N. S., Tailor, P., & Kumar, H. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.461 · Cited by 52
Self-citationTakemoto, M., Koike, M., Mori, Y., Yonemoto, S., Sasamoto, Y., Kondo, K., Uchiyama, Y., & Yamanishi, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.20.13037-13046.2005 · Cited by 55
Terrier, O., Josset, L., Textoris, J., Marcel, V., Cartet, G., Ferraris, O., Nguyen, C., Lina, B., Diaz, J., Bourdon, J., et al. (2011) · Virology Journal · doi:10.1186/1743-422x-8-285 · Cited by 54
Han, W., Qiu, H.-Y., Sun, S., Fu, Z.-C., Wang, G., Qian, X., Wang, L., Zhai, X., Jia, W. P., Wang, Y., et al. (2023) · Cell stem cell · doi:10.1016/j.stem.2023.10.007 · Cited by 55
Al‐Haj, L., Blackshear, P. J., & Khabar, K. S. A. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks545 · Cited by 54
Different Requirements for the Cytostatic and Apoptotic Effects of Type I Interferons
Sandoval, R., Xue, J., Pilkinton, M. A., Salvi, D., Kiyokawa, H., & Colamonici, O. R. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313830200 · Cited by 59
Acetylation is indispensable for p53 antiviral activity
Muñoz‐Fontela, C., de Llano, D. G., Marcos-Villar, L., Campagna, M., Gallego, P. P. F., González, J., Herranz, D., Gu, W. J., Serrano, M., Aaronson, S. A., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.21.17899 · Cited by 54
Effect and Safety of Interferon for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Zhuang, L., Zeng, X., Yang, Z., & Meng, Z. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061361 · Cited by 53
Zheng, X., Yan, J., You, W., Li, F., Diao, J., He, W., & Yao, Y. (2021) · Small · doi:10.1002/smll.202100394 · Cited by 56
Modulation of p53 Cellular Function and Cell Death by African Swine Fever Virus
Granja, A. G., Nogal, M. L., Hurtado, C., Salas, J., Salas, M. L., Carrascosa, Á. L., & Revilla, Y. (2004) · Journal of Virology · doi:10.1128/jvi.78.13.7165-7174.2004 · Cited by 61
Alternative Signaling Pathways Regulating Type I Interferon-Induced Apoptosis
Tamm, K. P., Panaretakis, T., & Grandér, D. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.799 · Cited by 54
Retinoic-acid-induced apoptosis in leukemia cells
Jimenez-Lara, A. M., Clarke, N., Altucci, L., & Gronemeyer, H. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.08.006 · Cited by 59
Adaptive homeostasis and the p53 isoform network
Mehta, S., Campbell, H., Drummond, C. J., Li, K., Murray, K., Slatter, T., Bourdon, J., & Braithwaite, A. W. (2021) · EMBO reports · doi:10.15252/embr.202153085 · Cited by 49
Nagano, H., Wada, H., Kobayashi, S., Marubashi, S., Eguchi, H., Tanemura, M., Tomimaru, Y., Osuga, K., Umeshita, K., Doki, Y., et al. (2011) · Oncology · doi:10.1159/000328281 · Cited by 50
Bhowmick, R., Halder, U. C., Chattopadhyay, S., Nayak, M. K., & Chawla‐Sarkar, M. (2013) · Journal of Virology · doi:10.1128/jvi.00734-13 · Cited by 57
Lymphocyte apoptosis as an immune subversion strategy of microbial pathogens
Carrero, J. A., & Unanue, E. R. (2006) · Trends in Immunology · doi:10.1016/j.it.2006.09.005 · Cited by 50
Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy
Bressy, C., Hastie, E. L., & Grdzelishvili, V. Z. (2017) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2017.03.002 · Cited by 58
INI1 Induces Interferon Signaling and Spindle Checkpoint in Rhabdoid Tumors
Morozov, A., Lee, S. J., Zhang, Z., Cimica, V., Zagzag, D., & Kalpana, G. V. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0054 · Cited by 50
Measles Virus V Protein Inhibits p53 Family Member p73
Cruz, C. D., Palosaari, H., Parisien, J.-P., Devaux, P., Cattaneo, R., Ouchi, T., & Horvath, C. M. (2006) · Journal of Virology · doi:10.1128/jvi.02400-05 · Cited by 54
Burch, L. R., Scott, M. T., Pöhler, E., Meek, D. W., & Hupp, T. R. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.10.081 · Cited by 60
Wang, X., Deng, X., Yan, W., Zhu, Z., Yang, S., Qiu, Y., Shi, Z., Shao, D., Wei, J., Xia, X., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.335422 · Cited by 52
Mapping the p53 transcriptome universe using p53 natural polymorphs
Wang, B., Niu, D., Lam, T. H., Xiao, Z., & Ren, E. C. (2013) · Cell Death and Differentiation · doi:10.1038/cdd.2013.132 · Cited by 52
Long story short: p53 mediates innate immunity
Miciak, J., & Bunz, F. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.03.001 · Cited by 50
Bileck, A., Kreutz, D., Muqaku, B., Slany, A., & Gerner, C. (2014) · Journal of Proteome Research · doi:10.1021/pr5008625 · Cited by 49
Pierce, A. T., DeSalvo, J., Foster, T. P., Kosinski, A., Weller, S. K., & Halford, W. P. (2005) · Journal of General Virology · doi:10.1099/vir.0.80979-0 · Cited by 49
Müller, D. B., Raftery, M. J., Kather, A., Giese, T., & Schönrich, G. (2004) · European Journal of Immunology · doi:10.1002/eji.200324509 · Cited by 49
Essential contribution of IRF3 to intestinal homeostasis and microbiota-mediated Tslp gene induction
Negishi, H., Miki, S., Sarashina, H., Taguchi-Atarashi, N., Nakajima, A., Matsuki, K., Endo, N., Yanai, H., Nishio, J., Honda, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219482110 · Cited by 45
Self-citationYan, W., Wei, J., Deng, X., Shi, Z., Zhu, Z., Shao, D., Li, B., Wang, S., Tong, G., & Ma, Z. (2015) · BMC Medical Genomics · doi:10.1186/s12920-015-0127-8 · Cited by 53
Tetracycline and viruses: a possible treatment for COVID-19?
Mosquera-Sulbarán, J., & Hernández–Fonseca, H. (2020) · Archives of Virology · doi:10.1007/s00705-020-04860-8 · Cited by 52
Maeda, S., Wada, H., Naito, Y., Nagano, H., Simmons, S., Kagawa, Y., Naito, A., Kikuta, J., Ishii, T., Tomimaru, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551879 · Cited by 48
“Expression of p53, which has been reported to play a central role in cell cycle arrest and apoptotic induction (6), was unaltered in HuH7 cells treated by IFN- , irrespective of the cell cycle status (Fig.”
BackgroundHeiber, J. F., & Barber, G. N. (2011) · Journal of Virology · doi:10.1128/jvi.05408-11 · Cited by 49
Intralesional Interferon-α for Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma
Blasi, M. A., Tiberti, A., Valente, P., Laguardia, M., Sammarco, M. G., Balestrazzi, A., Larocca, L. M., & Balestrazzi, E. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.09.008 · Cited by 48
Spring viraemia of carp virus modulates p53 expression using two distinct mechanisms
Li, S., Lu, L.-F., Liu, S.-B., Zhang, C., Li, Z.-C., Zhou, X.-Y., & Zhang, Y. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007695 · Cited by 49
Local tumour ablative therapies: Opportunities for maximising immune engagement and activation
O'Brien, M. A., Power, D. G., Clover, A. J. P., Bird, B., Soden, D. M., & Forde, P. F. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.09.005 · Cited by 56
“cells to DNA damage [32] but it seems that their major contribution to anti-cancer immunity is their actions on haematopoietic cells.”
BackgroundDNA damage signalling recruits RREB-1 to the p53 tumour suppressor promoter
Liu, H., Hew, H. C., Lu, Z., Yamaguchi, T., Miki, Y., & Yoshida, K. (2009) · Biochemical Journal · doi:10.1042/bj20090342 · Cited by 51
Ranuncolo, S. M., Ling, W., Polo, J. M., Dell’Oso, T., Dierov, J. K., Gaymes, T. J., Rassool, F. V., Carroll, M. P., & Melnick, A. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803490200 · Cited by 50
IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytes
DeCarlo, C. A., Severini, A., Edler, L., Escott, N. G., Lambert, P. F., Ulanova, M., & Zehbe, I. (2010) · Laboratory Investigation · doi:10.1038/labinvest.2010.95 · Cited by 47
Pozharskaya, V. P., Weakland, L. L., Zimring, J. C., Krug, L. T., Unger, E. R., Neisch, A., Joshi, H. C., Inoue, N., & Offermann, M. K. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6621-6635.2004 · Cited by 48
Xin, H., D’Souza, S., Jørgensen, T. N., Vaughan, A. T., Lengyel, P., Kotzin, B. L., & Choubey, D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.10.5863 · Cited by 52
Interferon responses in viral pneumonias
Grajales-Reyes, G. E., & Colonna, M. (2020) · Science · doi:10.1126/science.abd2208 · Cited by 46
Interferons and interferon-related pathways in heart disease
Tran, D. T., Batchu, S. N., & Advani, A. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1357343 · Cited by 48
Type I Interferons Control Proliferation and Function of the Intestinal Epithelium
Katlinskaya, Y. V., Katlinski, K. V., Lasri, A., Li, N., Beiting, D. P., Durham, A. C., Yang, T., Pikarsky, E., Lengner, C. J., Johnson, F. B., et al. (2016) · Molecular and Cellular Biology · doi:10.1128/mcb.00988-15 · Cited by 47
Hebner, C. M., Beglin, M., & Laimins, L. A. (2007) · Journal of Virology · doi:10.1128/jvi.00987-07 · Cited by 51
Metadata
- Authors
- Takaoka, A., Hayakawa, S., Yanai, H., Stoiber, D., Negishi, H., Kikuchi, H., Sasaki, S., Imai, K., Shibue, T., Honda, K., & Taniguchi, T.
- Affiliations
- The University of Tokyo (JP)
- University of Vienna (AT)
- Sapporo Medical University (JP)
- Corresponding author
- Taniguchi, Tadatsugu
- ORCID
- Venue
- Nature
- Published
- 2003-07
- Volume
- 424
- Issue
- 6948
- Pages
- 516-523
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2119885778
- Cited by
- 847
- References
- 51
- Citations by year
- 2026: 13 · 2025: 18 · 2024: 20 · 2023: 25 · 2022: 22 · 2021: 32 · 2020: 41 · 2019: 40 · 2018: 21 · 2017: 38 · 2016: 50 · 2015: 44 · 2014: 40 · 2013: 46 · 2012: 38
- FWCI
- 20.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Boehringer Ingelheim Japan
- Senri Life Science Foundation
- Kanae Foundation for the Promotion of Medical Science
- Japan Society for the Promotion of Science
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- p53, type I interferon, interferon signaling, tumor suppression, antiviral defense, apoptosis, viral infection, cancer therapy
- MeSH terms
- Animals, Cell Transformation, Neoplastic, DNA-Binding Proteins, Humans, Mice, Inbred C57BL, Neoplasms, RNA, Messenger, Transcription Factors, Transcription, Genetic, Tumor Cells, Cultured, Vesicular stomatitis Indiana virus, Signal Transduction, Transcriptional Activation, Gene Expression Regulation, Neoplastic, Tumor Suppressor Protein p53, Interferon-alpha, Interferon-beta, Apoptosis, Response Elements, Interferon-Stimulated Gene Factor 3, Interferon-Stimulated Gene Factor 3, gamma Subunit, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.